dCBP-1 manufacturers
- dCBP-1
-
- $0.00 / 100MG
-
2024-08-26
- CAS:2484739-25-3
- Min. Order: 1MG
- Purity: 98
- Supply Ability: 100G
|
| Product Name: | dCBP-1 | | Synonyms: | 5H-Pyrazolo[4,3-c]pyridine-5-carboxamide, 3-[7-(difluoromethyl)-3,4-dihydro-6-(1-methyl-1H-pyrazol-4-yl)-1(2H)-quinolinyl]-1-[1-[15-[[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1H-isoindol-5-yl]amino]-1-oxo-4,7,10,13-tetraoxapentadec-1-yl]-4-piperidinyl]-1,4,6,7-tetrahydro-N-methyl-;dCBP-1;3-(7-(Difluoromethyl)-6-(1-methyl-1H-pyrazol-4-yl)-3,4-dihydroquinolin-1(2H)-yl)-1-(1-(1-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)amino)-3,6,9,12-tetraoxapentadecan-15-oyl)piperidin-4-yl)-N-methyl-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;Inhibitor,p300,multiple,CRBN,myeloma,cell,degrader,PROTACs,MYC,CBP,inhibit,dCBP 1,dCBP1,heterobifunctional,Epigenetic Reader Domain,dCBP-1 | | CAS: | 2484739-25-3 | | MF: | C51H63F2N11O10 | | MW: | 1028.11 | | EINECS: | | | Product Categories: | | | Mol File: | 2484739-25-3.mol |  |
| | dCBP-1 Chemical Properties |
| density | 1.47±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C, sealed storage, away from moisture and light | | solubility | DMSO : 50 mg/mL (48.63 mM; ultrasonic and warming and heat to 80°C) | | form | Solid | | pka | 10.80±0.40(Predicted) | | color | Light yellow to yellow | | InChIKey | ILVRLRGBSSFKIE-UHFFFAOYSA-N | | SMILES | C1N(C(NC)=O)CCC2N(C3CCN(C(=O)CCOCCOCCOCCOCCNC4C=CC5=C(C=4)C(=O)N(C4CCC(=O)NC4=O)C5=O)CC3)N=C(N3C4=C(C=C(C5=CN(C)N=C5)C(C(F)F)=C4)CCC3)C1=2 |
| | dCBP-1 Usage And Synthesis |
| Uses | dCBP-1 is exceptionally potent at killing multiple myeloma cells and can abolish the enhancer that drives MYC oncogene expression. As an efficient degrader of this unique class of acetyltransferases, dCBP-1 is a useful tool alongside domain inhibitors for dissecting the mechanism by which these factors coordinate enhancer activity in normal and diseased cells.
| | Biological Activity | dCBP-1 is a potent and selective heterobifunctional degrader of p300/CBP based on PROTAC. dCBP-1 is exceptionally potent at killing multiple myeloma cells and ablates oncogenic enhancer activity driving MYC expression[1].
dCBP-1 (10-1000 nM; 6 hours) treatment shows near-complete degradation of p300/CBP in MM1S cells. dCBP-1 is also able to induce near-complete p300/CBP degradation across other multiple myeloma cell lines tested, including MM1R, KMS-12-BM, and KMS34[1].Treatment of the human haploid cell line HAP1 for 6 h with dCBP-1 reveals almost complete loss of both CBP and p300 between 10 and 1000 nM doses. A time course analysis with 250 nM dCBP-1 revealed almost complete degradation of p300/CBP within an hour of treatment[1]. | | Synthesis | 3-(7-(difluoromethyl)-6-(1-methyl-1H-pyrazol-4-yl)-3,4-dihydroquinolin-1(2H)-yl)-1-(1-(1-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)amino)-3,6,9,12-tetraoxapentadecan-15-oyl)piperidin-4-yl)-N-methyl-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide dCBP-1: The compound tert-butyl 3-(7-(difluoromethyl)-6-(1-methyl-1H-pyrazol-4-yl)-3,4-dihydroquinolin-1(2H)-yl)-1-(1-(1-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)amino)-3,6,9,12-tetraoxapentadecan-15-oyl)piperidin-4-yl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxylate S18 (0.010 g, 0.01 mmol) was dissolved in 1:1 DCM: TFA (1 mL) and stirred for 30 min. The solvents were evaporated under reduced pressure, and the crude reaction mixture was dissolved in DCM (1 mL), TEA (0.1 mL), and N-methyl-1H-imidazole-1-carboximide (3.5 mg, 0.03 mmol) was added at RT and stirred overnight. Volatiles were evaporated, and the crude reaction mixture was purified by ISCO using C18 (14g) column, 0-100% MeOH/water to yield dCBP-1 (0.008 g, 80%) as a yellow oil. | | References | [1]. Raghu Vannam, et al. Targeted degradation of the enhancer lysine acetyltransferases CBP and p300. Cell Chem Biol. 2020 Dec 31;S2451-9456(20)30513-4. |
| | dCBP-1 Preparation Products And Raw materials |
|